IBS, Crohn, Colitis & Bowel Disorders • ICD-10-CM K64.0
First degree hemorrhoids
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM K64.0 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Devon Caldwell, DO, MPH (NPI #1568063758)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
First degree hemorrhoids Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as K64.0, First degree hemorrhoids falls under IBS, IBD & Colon management, where targeted soluble fiber/low-FODMAP in First degree hemorrhoids (K64.0: dietary titration) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry K64.0: First degree hemorrhoids is managed within IBS, IBD & Colon.
- 3 Typical cash cost range: Workup highlights for First degree hemorrhoids (K64.0): targeted soluble fiber/low-FODMAP in First degree hemorrhoids (K64.0: dietary titration).
- 4 Top reported side effects / signs: Objective lab/clinical target for First degree hemorrhoids: Tissue Transglutaminase IgA in First degree hemorrhoids (K64.0: (tTG-IgA)) (Negative (celiac rule-out) (K64.0)) and hs-CRP, CBC & in First degree hemorrhoids (K64.0: Ferritin).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about First degree hemorrhoids
What Is First degree hemorrhoids?
Designated in federal medical registries as K64.0, First degree hemorrhoids falls under IBS, IBD & Colon management, where targeted soluble fiber/low-FODMAP in First degree hemorrhoids (K64.0: dietary titration) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in ibs, ibd & colon, First degree hemorrhoids (K64.0) involves mucosal tight-junction permeability in First degree hemorrhoids (K64.0: shifts or immune-mediated). progression correlates with shifts in Tissue Transglutaminase IgA in First degree hemorrhoids (K64.0: (tTG-IgA)) (Negative (celiac rule-out) (K64.0)).
Common Symptoms & Clinical Signs
- • Presentation of First degree hemorrhoids (K64.0): alternating diarrhea, constipation, in First degree hemorrhoids (K64.0: urgency, or sensation)
- • Secondary First degree hemorrhoids clinical sign: post-meal abdominal distension, in First degree hemorrhoids (K64.0: gas bloating, or)
- • Symptom flares in First degree hemorrhoids correlating with Tissue Transglutaminase IgA in First degree hemorrhoids (K64.0: (tTG-IgA)) deviation outside Negative (celiac rule-out) (K64.0)
- • Functional ibs, ibd & colon impact requiring targeted soluble fiber/low-FODMAP in First degree hemorrhoids (K64.0: dietary titration) evaluation (K64.0)
First degree hemorrhoids Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K64.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | IBS, Crohn, Colitis & Bowel Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Tissue Transglutaminase IgA in First degree hemorrhoids (K64.0: (tTG-IgA)) | Negative (celiac rule-out) (K64.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP, CBC & in First degree hemorrhoids (K64.0: Ferritin) | Normal hemoglobin; hs-CRP < 1.0 mg/L (K64.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fecal Calprotectin [First degree hemorrhoids K64.0] | < 50 mcg/g (K64.0) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for First degree hemorrhoids
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Neosporin Kids Plus Pain Relief (Neomycin Sulfate, Polymyxin B Sulfate, and Pramoxine Hydrochloride) Neosporin Kids Plus Pain Relief • RxCUI 1359360-B699680054 | Aminoglycoside Antibacterial | 91% | $0.1887 | $ 22.09 /mo |
| Norethindrone Errin, Incassia • RxCUI 198042 | Progestin | 77% | $0.0849 | $ 6.46 /mo |
| Sheffield Triple Antibiotic (Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate) Sheffield Triple Antibiotic • RxCUI 204602-B11527162 | Aminoglycoside Antibacterial | 77% | $0.0856 | $ 14.66 /mo |
| First Aid Antibiotic and Pain Relief (Neomycin, Polymyxin B, Pramoxine HCl) First Aid Antibiotic and Pain Relief • RxCUI 1359360 | Aminoglycoside Antibacterial | 85% | $5.3182 | $ 391.41 /mo |
| Zolbetuximab Vyloy • RxCUI 2695876 | Claudin 18.2-directed Cytolytic Antibody | 83% | $0.6700 | $ 35.64 /mo |
| Hydrocortisone Acetate Medi-First Hydrocortisone 1%, Medi First Plus • RxCUI 1291082 | Corticosteroid | 88% | $0.0537 | $ 6.55 /mo |
| First Aid Only Antacid (Calcium Carbonate) First Aid Only Antacid • RxCUI 313884 | Blood Coagulation Factor | 88% | $2.6700 | $ 200.74 /mo |
| Honestly Battleborn First Aid for Real Man (Tetracycline Hydrochloride) Honestly Battleborn First Aid for Real Man • RxCUI 1542813 | Tetracycline-class Antimicrobial | 87% | $0.5820 | $ 50.41 /mo |
| Genuine First Aid Alcohol Cleansing Pad (Benzocaine, Alcohol) Genuine First Aid Alcohol Cleansing Pad • RxCUI 1046313-B50814080 | Standardized Chemical Allergen | 76% | $2.9300 | $ 219.46 /mo |
| Naloxone Hci Naloxone Hci Generic • RxCUI RXN-516621242-2943 | Opioid Antagonist | 74% | $15.4207 | $ 185.00 /mo |
| Amivantamab-Vmjw Rybrevant • RxCUI 2549734 | FDA Prescription Therapeutic Agent | 90% | $1.3900 | $ 64.79 /mo |
| Irinotecan Hydrochloide Irinotecan Hydrochloide Generic • RxCUI 1726319 | Topoisomerase Inhibitor | 76% | $0.5000 | $ 28.75 /mo |
| Tetracyte First Aid and Antibiotic Topical (Tetracycline Hydrochloride) Tetracyte First Aid and Antibiotic Topical • RxCUI 1542813-B71262011 | Tetracycline-class Antimicrobial | 87% | $0.5820 | $ 50.41 /mo |
| Afatinib Gilotrif • RxCUI 1430446 | Kinase Inhibitor | 94% | $2.8000 | $ 121.90 /mo |
| Medique Cold Eeze (Zinc Gluconate) Medique Cold Eeze • RxCUI RXN-B47682478 | Copper Absorption Inhibitor | 84% | $0.0158 | $ 9.64 /mo |
| First Degree (Calendula Officinalis, Echinacea Angustifolia, Cantharis Vesicatoria) First Degree • RxCUI RXN-B24330110 | Over-the-Counter Clinical Monograph | 75% | $1.6500 | $ 127.30 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (First degree hemorrhoids)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| Can This Approach Help? Inside the Latest Research on [World Report] First human case of Shamonda virus A patient in France has died from the infection, which normally affects cattle. Virologists say the wider risk to public health is low. Marianne Guenot reports. The Lancet • 2026-10-31 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID LANCET-2806831375 ↗ |
| New Insights on Veliparib concomitant with first-line chemotherapy and as maintenance therapy in: What a 1,140-Participant Study Found No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed. European journal of cancer (Oxford, England : 1990) • 2025-07-25 • Phase III Randomized Trial | N = 1,140 | 96/100 | PMID 40561681 ↗ |
| New Insights on Phase III Study to Evaluate real-world benefits and safety of Andecaliximab With: What a 432-Participant Study Found The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-03-20 • Phase III Randomized Trial | N = 432 | 93/100 | PMID 33577358 ↗ |
| New Insights on Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction: What a 674-Participant Study Found UPA45 provided rapid relief of clinical symptoms within the first week of treatment in patients with CD. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-08-15 • Phase III Randomized Trial | N = 674 | 93/100 | PMID 38492903 ↗ |
Zero-PHI Patient Support & Cohort Discussions
First degree hemorrhoids Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter First degree hemorrhoids community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about First degree hemorrhoids.